11.75
Bicara Therapeutics Inc Aktie (BCAX) Neueste Nachrichten
What analysts say about Bicara Therapeutics Inc. stock outlookHigh-margin investment plays - jammulinksnews.com
Is Bicara Therapeutics Inc. stock a good hedge against inflationExtraordinary profit generation - jammulinksnews.com
Will Bicara Therapeutics Inc. stock benefit from interest rate changesDynamic investment growth - jammulinksnews.com
Is Bicara Therapeutics Inc. a good long term investmentConsistently exceptional gains - Autocar Professional
Bicara Therapeutics Inc. Stock Analysis and ForecastFree Investment Community - jammulinksnews.com
What drives Bicara Therapeutics Inc. stock priceHigh-velocity gains - jammulinksnews.com
What analysts say about Bicara Therapeutics Inc. stockHigh-profit trading signals - jammulinksnews.com
How Bicara Therapeutics Inc. stock performs during market volatilityVolume Spike Monitors - Newser
Analysts Set Bicara Therapeutics Inc. (NASDAQ:BCAX) Price Target at $31.86 - Defense World
Why Bicara Therapeutics Inc. stock attracts strong analyst attentionFree Step-by-Step Investment Guide - Newser
What makes Bicara Therapeutics Inc. stock price move sharplyInvestor Friendly Risk Reward - Newser
Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III - Yahoo Finance
GAMMA Investing LLC Purchases 7,694 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Elects New Directors at Annual Meeting - TipRanks
Petri Dish: Scorpion spinout debuts with $177M, Bicara doubles footprint - The Business Journals
# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trial - Investing.com
Relay Therapeutics Strengthens Board with Precision Medicine Expert as Phase 3 Cancer Trial Approaches - Stock Titan
Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus (NASDAQ:BCAX) - Seeking Alpha
Bicara Therapeutics Inc. (NASDAQ:BCAX) Holdings Raised by Bank of America Corp DE - Defense World
Cantor Fitzgerald Estimates BCAX FY2026 Earnings - Defense World
Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update - MSN
Stifel maintains Buy rating, $48 target on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):